Bargain hunters are wise to pay careful attention to insider buying, because although there are many various reasons for an insider to sell a stock, presumably the only reason they would use their hard-earned dollars to make a purchase, is that they expect to make money.
Today we look at two noteworthy recent insider buys.
Bargain hunters are wise to pay careful attention to insider buying, because although there are many various reasons for an insider to sell a stock, presumably the only reason they would use their hard-earned dollars to make a purchase, is that they expect to make money.
Today we look at two noteworthy recent insider buys.
At Neuronetics, a filing with the SEC revealed that on Monday, Director Robert Cascella bought 15,000 shares of STIM, for a cost of $6.72 each, for a total investment of $100,850.
Cascella was up about 19.1% on the purchase at the high point of today's trading session, with STIM trading as high as $8.01 in trading on Wednesday.
Neuronetics is trading up about 13.5% on the day Wednesday.
This purchase marks the first one filed by Cascella in the past year.
And at Cardlytics, there was insider buying on Monday, by Director John V.
Balen who bought 1,000 shares at a cost of $89.85 each, for a trade totaling $89,850.
Before this latest buy, Balen bought CDLX on 2 other occasions during the past year, for a total cost of $447,617 at an average of $89.52 per share.
Cardlytics is trading up about 3.4% on the day Wednesday.
Balen was up about 5.4% on the purchase at the high point of today's trading session, with CDLX trading as high as $94.66 in trading on Wednesday.